Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia
about
sameAs
Essential thrombocythemiaPolycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and managementAconitase regulation of erythropoiesis correlates with a novel licensing function in erythropoietin-induced ERK signaling.Coronary artery intervention after cytostatics treatment in unstable angina patient with essential thrombocythemia. A case report and literature reviewPulmonary hypertension in patients with essential thrombocythemia and reactive thrombocytosisAnagrelide for the treatment of essential thrombocythemia: a survey among European hematologists/oncologistsGuideline on the clinical use of apheresis procedures for the treatment of patients and collection of cellular therapy products. British Committee for Standards in Haematology.Thrombocytopenia in the intensive care unit.Nadroparine-induced skin necrosis on a patient with essential thrombocythaemia: a case reportMulticenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms.Acute ST-segment elevation myocardial infarction in a young patient with essential thrombocythemia: a case with long-term follow-up reportPostpartal recurrent non-ST elevation myocardial infarction in essential thrombocythaemia: case report and review of the literature.Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked.Severe delayed postpolypectomy bleeding in elder patient with post-polycythemia myelofibrosisCoronary spasm-related acute myocardial infarction in a patient with essential thrombocythemia.Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies.Neurological disorders in essential thrombocythemia.Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinibInfluence of the JAK2 V617F Mutation and Inherited Thrombophilia on the Thrombotic Risk among Patients with Myeloproliferative Disorders.Transient ischemic attacks as the first presentation of JAK2-V617F positive chronic myeloproliferative neoplasm.Essential thrombocythaemia: challenges and evidence-based management.Comprehensive Gene expression meta-analysis and integrated bioinformatic approaches reveal shared signatures between thrombosis and myeloproliferative disorders.Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemiaAnagrelide for control of thrombocytosis due to myeloproliferative disorders.Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia.Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.Evolving management of essential thrombocythaemia.Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia.Early recognition of intraventricular hemorrhage in the setting of thrombocytosis in the emergency department.γ-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative Neoplasm.JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasmsAssociation between sex steroid hormones and hematocrit in a nationally representative sample of menInfluence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia.Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia.JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia.Anagrelide: 20 years later.Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms.Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.Role of platelet counts in the management of essential thrombocythemia: experience with anagrelide.
P2860
Q21202968-5B375383-9D30-4CEC-A52D-2AC0BD754D97Q26851894-47B4B023-652E-4DF0-BD46-47AC21C03D20Q27323049-6597AE11-59B5-4F27-82C6-0017431CAF9CQ28200160-92E46E8D-EEE0-4C07-9F70-477C61ED689BQ28221431-C56EFDAF-680D-4B99-AF45-7C5DB45AB431Q28307195-60BA54A2-2C0B-40F9-BBE4-4FC8A2D3D948Q33165774-CA306258-D26E-4CBC-A8AB-DCB67AA0C73FQ33399094-91E1F603-5F63-43BA-BC62-B5C58A1B65FBQ33681684-27EDCC6C-DFA4-4AF4-A565-70BAA6EE1E6FQ33747797-4E3DD06E-45D6-4DC7-926B-67AEA286AFADQ33968801-A1E4D816-435E-4D84-9E9D-F74CC2C56AC6Q34016598-3CFE21A6-C488-4D48-8F1E-4C6ECCC32097Q34122035-67412648-1D57-4D2F-8A0F-BBC7897B0C79Q34166617-67C0B9E8-3390-47DB-9950-ABC77CFBAEC2Q35051441-901A3303-D0D9-4615-8E36-59CFF7FDD618Q35185101-56EC05CA-C1F2-4AEE-AD7F-7E007B763AA8Q35433259-3E97B6D8-6694-47B7-8914-1724E04EC853Q35596951-1BEC4C1C-EF1B-4EC4-AD02-B451DEF8E816Q35732435-5D19E7C1-270D-426E-ABA4-73B7475086C3Q35834175-D9709A9E-83D9-4487-980C-B5648C7AC444Q36106171-3B90151F-A9AA-4BCF-B2AD-88FF091637A4Q36200476-8C7FC09F-5F83-4F5E-AF10-FB4392837A4AQ36205153-7814D819-2D2F-40DC-A754-E4AF375EDADCQ36404698-9B07386E-BF6F-42FD-BBDC-DB31E871AEB9Q36429566-E8650D9E-5574-4DEF-9572-FC58FA8A7031Q36455487-29DD54CE-8F0C-4FE1-ADF4-092A676E8FF3Q36654317-964261D6-7991-45C8-A98F-525C8EE3940DQ36922497-B279BB1D-FB38-4B4F-80BF-26EF4791C7EBQ36941052-4DDBC452-F25A-4494-B8D4-9CB20F28B62DQ36949737-CAEC0491-EB60-4011-8CEB-1A0686645E58Q36993026-4D08656A-91A1-4F36-ACA7-94C6E43DB2DAQ37168138-8EC4A741-A3E6-4726-A783-8F3B3A2D2FC7Q37173909-DCBC431A-9BB9-4AD9-926C-FEF861C3267DQ37175624-40C2854A-2928-45D9-8593-9726D7D2C40BQ37246729-B4DBEA24-DD8D-4B83-952F-4DC2E592BED1Q37349414-AF1AACA5-1607-4714-9516-34F42D384107Q37357291-2E9E1E2E-E583-4AC8-BA0F-96310F2524E6Q37417438-A5C043D7-D416-4B0B-90B0-A92C445B1033Q37661411-ED3D9764-998E-40FC-942F-8CC72E0F6ADBQ37810089-B68316A4-0E51-4823-8320-977EDAD92A9F
P2860
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia
@ast
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia
@en
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia
@nl
type
label
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia
@ast
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia
@en
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia
@nl
prefLabel
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia
@ast
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia
@en
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia
@nl
P2860
P3181
P1476
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia
@en
P2093
M A Elliott
P2860
P304
P3181
P356
10.1111/J.1365-2141.2004.05277.X
P407
P577
2005-02-01T00:00:00Z